Y-Intercept (HK)’s Celldex Therapeutics CLDX Stock Holding History

Y-Intercept (HK)’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.46M	Buy	75,976 +43,719	+136%	+$1.67M	0.05%	518
2026 Q2	$1.2M	Sell	32,257 -12,935	-29%	-$418K	0.02%	964
2026 Q1	$1.43M	Buy	+45,192	New	+$1.23M	0.03%	883
2025 Q4	–	Sell	-48,906	Closed	-$1.27M	–	1601
2025 Q3	$1.27M	Sell	48,906 -9,492	-16%	-$220K	0.03%	861
2025 Q2	$1.19M	Buy	+58,398	New	+$1.14M	0.03%	856
2024 Q4	–	Sell	-30,538	Closed	-$1.04M	–	1246
2024 Q3	$1.04M	Buy	30,538 +3,146	+11%	+$120K	0.06%	435
2024 Q2	$1.01M	Buy	+27,392	New	+$1.03M	0.06%	487

Other funds holding CLDX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Y-Intercept (HK)'s CLDX Position: Q3 2026 in Review

Y-Intercept (HK) increased its Celldex Therapeutics (CLDX) stake by 136% in Q3 2026, buying an estimated $1.67M and bringing the position to 75,976 shares worth $2.46M. The position accounts for 0.05% of the portfolio, ranked #518.

Y-Intercept (HK) first reported a position in CLDX in Q2 2024 and has held it in 7 quarters since. 26 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Y-Intercept (HK) held 75,976 shares of Celldex Therapeutics worth $2.46M as of Q3 2026.
Y-Intercept (HK) bought 43,719 Celldex Therapeutics shares in Q3 2026, an estimated $1.67M.
Celldex Therapeutics made up 0.05% of Y-Intercept (HK)'s portfolio in Q3 2026, its #518 holding.
Y-Intercept (HK) first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 7 quarters since.
26 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.